Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

ClinicalTrials.gov ID: NCT02555683

Public ClinicalTrials.gov record NCT02555683. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016) in the following two populations: * patient with inadequately controlled severe asthma and high eosinophil counts at baseline (eosinophil count at Visit 1 ≥250 cells/ µl) (sub-population) * patients with inadequately controlled severe asthma (overall study population) Inadequate control is defined as partly controlled or uncontrolled asthma (GINA 2016).

Study identification

NCT ID
NCT02555683
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
894 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 10, 2015
Primary completion
Oct 20, 2019
Completion
Nov 3, 2019
Last update posted
May 17, 2020

2015 – 2019

United States locations

U.S. sites
55
U.S. states
21
U.S. cities
52
Facility City State ZIP Site status
Novartis Investigative Site Birmingham Alabama 35209
Novartis Investigative Site Birmingham Alabama 35249
Novartis Investigative Site Gilbert Arizona 85234
Novartis Investigative Site Litchfield Park Arizona 85340
Novartis Investigative Site Peoria Arizona 85381
Novartis Investigative Site Little Rock Arkansas 72209
Novartis Investigative Site Hawaiian Gardens California 90716
Novartis Investigative Site Newport Beach California 92663
Novartis Investigative Site Redondo Beach California 90277
Novartis Investigative Site Riverside California 92506
Novartis Investigative Site Torrance California 90503
Novartis Investigative Site Westminster California 92683
Novartis Investigative Site New Haven Connecticut 06520
Novartis Investigative Site Brandon Florida 33511
Novartis Investigative Site New Smyrna Beach Florida 32168
Novartis Investigative Site Orlando Florida 32803
Novartis Investigative Site Orlando Florida 32806
Novartis Investigative Site Ormond Beach Florida 32174
Novartis Investigative Site Sebring Florida 33870
Novartis Investigative Site Winter Park Florida 32789
Novartis Investigative Site Gainesville Georgia 30501
Novartis Investigative Site Marietta Georgia 30060
Novartis Investigative Site Crowley Louisiana 70526
Novartis Investigative Site Zachary Louisiana 70791
Novartis Investigative Site Bangor Maine 04401
Novartis Investigative Site Gaithersburg Maryland 20878
Novartis Investigative Site White Marsh Maryland 21162
Novartis Investigative Site Livonia Michigan 48152
Novartis Investigative Site Ypsilanti Michigan 48197
Novartis Investigative Site Picayune Mississippi 39466
Novartis Investigative Site Bellevue Nebraska 68123
Novartis Investigative Site Lincoln Nebraska 68510
Novartis Investigative Site Omaha Nebraska 68131
Novartis Investigative Site Corning New York 14830
Novartis Investigative Site New York New York 10016
Novartis Investigative Site Charlotte North Carolina 28277
Novartis Investigative Site Gastonia North Carolina 28054
Novartis Investigative Site Monroe North Carolina 28112
Novartis Investigative Site New Bern North Carolina 28562
Novartis Investigative Site Whiteville North Carolina 28472
Novartis Investigative Site Wilmington North Carolina 28401
Novartis Investigative Site Winston-Salem North Carolina 27103
Novartis Investigative Site Canton Ohio 44718
Novartis Investigative Site Cincinnati Ohio 45231
Novartis Investigative Site Maumee Ohio 43537
Novartis Investigative Site Oklahoma City Oklahoma 73120
Novartis Investigative Site Jefferson Hills Pennsylvania 15025
Novartis Investigative Site Pittsburgh Pennsylvania 15213
Novartis Investigative Site East Providence Rhode Island 02941
Novartis Investigative Site Boerne Texas 78006
Novartis Investigative Site McKinney Texas 75069
Novartis Investigative Site Plano Texas 75093
Novartis Investigative Site San Antonio Texas 78229
Novartis Investigative Site San Antonio Texas 78251
Novartis Investigative Site Fairfax Virginia 22030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 178 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02555683, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 17, 2020 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02555683 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →